Related references
Note: Only part of the references are listed.Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study
Stefano Mazza et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe
Christian Agboton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
Jurij Hanzel et al.
INFLAMMATORY BOWEL DISEASES (2022)
INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: CLINICAL OUTCOMES IN REAL-WORLD PATIENTS FROM THE DANBIO REGISTRY
H. Nabi et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Eduardo Mysler et al.
DRUGS (2021)
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial
Hafsah Nabi et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
THE IBD BIOSIMILAR TO BIOSIMILAR SWITCHING STUDY (IBISS)
Clare Harris et al.
GUT (2021)
The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients
Nabeel Khan et al.
CROHNS & COLITIS 360 (2021)
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
P. Gisondi et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice
Ambre Lauret et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence
Brian G. Feagan et al.
ADVANCES IN THERAPY (2020)
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
Daniel F. Alvarez et al.
BIODRUGS (2020)
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study
Davide Giuseppe Ribaldone et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2020)
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Era of biosimilars in rheumatology: reshaping the healthcare environment
Josef S. Smolen et al.
RMD OPEN (2019)
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
Rieke Alten et al.
RMD OPEN (2019)
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4 Six-Month Results From a Controlled Cohort Study
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries
B. Glintborg et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2018)
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Stanley B. Cohen et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
Hendrik Schulze-Koops et al.
RHEUMATOLOGY (2017)
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Till Uhlig et al.
RHEUMATOLOGY (2017)
Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry
Else Helene Ibfelt et al.
CLINICAL EPIDEMIOLOGY (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The design of clinical trials to support the switching and alternation of biosimilars
Freddy Faccin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials
Priyanka Vashisht et al.
ARTHRITIS CARE & RESEARCH (2016)
Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Filipe C. Araujo et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO
Else Helene Ibfelt et al.
CLINICAL EPIDEMIOLOGY (2016)
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
Dae Hyun Yoo et al.
ARTHRITIS RESEARCH & THERAPY (2016)
The Danish National Patient Registry: a review of content, data quality, and research potential
Morten Schmidt et al.
CLINICAL EPIDEMIOLOGY (2015)
Inequities in access to biologic and synthetic DMARDs across 46 European countries
Polina Putrik et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The Danish Civil Registration System as a tool in epidemiology
Morten Schmidt et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
Share Paper
